Abstract: The present invention relates to an implant, in particular an intraluminal endoprothesis, comprising a body containing a metallic material, and comprising at least one functional element that is fastened to the body and has a material composition in at least a portion of its volume that differs from the material of the body, the material composition preferably including radio-opaque and/or x-ray opaque material. To effectively prevent accelerated degradation due to the formation of a local cell of the material of the body and the functional element, the at least one functional element includes a first layer at least in the region of its surface where it is bonded to the body, the first layer primarily containing at least one metal oxide. Furthermore, the manufacture of an implant of this type is described.

Abstract: The present invention relates to an implant, in particular an intraluminal endoprothesis, comprising a body containing a metallic material, and comprising at least one functional element that is fastened to the body and has a material composition in at least a portion of its volume that differs from the material of the body, the material composition preferably including radio-opaque and/or x-ray opaque material. To effectively prevent accelerated degradation due to the formation of a local cell of the material of the body and the functional element, the at least one functional element includes a first layer at least in the region of its surface where it is bonded to the body, the first layer primarily containing at least one metal oxide. Furthermore, the manufacture of an implant of this type is described.

Abstract: The present invention relates to a method of enhancing a pro-inflammatory immune response through the administration of the DEAD-box protein DDX3, as encoded by SEQ ID NO:1. The invention further extends to a method of suppressing an aberrant immune response, such at that associated with autoimmune conditions, through inhibition of DDX3. The invention also extends to a method of suppressing a pro-inflammatory immune response through the administration of the vaccinia virus protein K7. The invention further extends to the provision of an attenuated poxvirus wherein the K7R gene which encodes for the K7 protein is deleted or rendered non-functional. Pharmaceutical compositions comprising DDX3 inhibitory compounds, such as K7, are also provided.